Cargando…
Differential expression of prolyl hydroxylase 1 in patients with ulcerative colitis versus patients with Crohn’s disease/infectious colitis and healthy controls
BACKGROUND: Inhibition of prolyl hydroxylases (PHDs) leads to the induction of a transcriptional program that, in the gut, promotes intestinal epithelial cell survival. PHD inhibitors have recently been suggested as a promising alternative treatment for inflammatory bowel disease (IBD). In this stud...
Autores principales: | Van Welden, Sophie, Laukens, Debby, Ferdinande, Liesbeth, De Vos, Martine, Hindryckx, Pieter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842628/ https://www.ncbi.nlm.nih.gov/pubmed/24257430 http://dx.doi.org/10.1186/1476-9255-10-36 |
Ejemplares similares
-
Long-Term Environmental Hypoxia Exposure and Haematopoietic Prolyl Hydroxylase-1 Deletion Do Not Impact Experimental Crohn’s Like Ileitis
por: De Galan, Cara, et al.
Publicado: (2021) -
Dynamics of Prolyl Hydroxylases Levels During Disease Progression in Experimental Colitis
por: Bakshi, Hamid A., et al.
Publicado: (2019) -
Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions
por: Holvoet, Tom, et al.
Publicado: (2021) -
The HIF-prolyl hydroxylases have distinct and nonredundant roles in colitis-associated cancer
por: Kennel, Kilian B., et al.
Publicado: (2022) -
Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis
por: Keely, Simon, et al.
Publicado: (2013)